First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial - Paz-Ares, L G; Ramalingam, S S; Ciuleanu, T E (J Thorac Oncol, 2022)